Strategies for selective targeting of Auger electron emitters to tumor cells

Journal of Nuclear Medicine

Volumn 37, Issue 4 SUPPL., 1996, Pages

  O'Donoghue, Joseph A ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Auger electrons; DNA triplexes; Oligonucleotides

Indexed keywords

IDOXURIDINE; OLIGONUCLEOTIDE; RADIOACTIVE IODINE;

ARTICLE; ELECTRON; HUMAN; NEOPLASM; ONCOGENE MYC;

ELECTRONS; GENES, MYC; HUMANS; IDOXURIDINE; IODINE RADIOISOTOPES; NEOPLASMS; OLIGONUCLEOTIDES;

EID: 0030119257     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Humm JL, Charlton DE. A new calculational method to assess the therapeutic potential of Auger electron emission. Int J Radiat Oncol Biol Phys 1989;17:351-360.
2. Bloomer WD, McLaughlin WH, Weichselbaum RR, et al. Iodine-125-labeled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. Int J Radiat Biol 1980;38:197-202.
3. DeSombre ER, Shafii B, Hanson RN, Kuivanen PC, Hughes A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res 1992;52:5752-5758.
4. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci USA 1986;83:3728-3732.
5. Lovqvist A, Lindstrom A, Carlsson J. Binding, internalization and excretion of TGF alpha-dextran associated radioactivity in cultured human glioma cells. Cancer Biother 1993;8:345-356.
6. Martin RF, Maschine WA. Range of radiochemical damage to DNA with decay of iodine-125. Science 1981;213:896-898.
7. Hanvey JC, Peffer NJ, Bisi JE, et al. Antisense and antigene properties of peptide nucleic acids. Science 1992;258:1481-1485.
8. Moser HE, Dervan PB. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 1987;238:645-650.
9. Deal PA, Dervan PB. Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation. Science 1991;251:1360-1363.
10. Loke SL, Stein CA, Zhang XH, et al. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 1989;86:3474-3478.
11. Ibson JM, Rabbitts PH. Sequence of a germ-line N-myc gene and amplification as a mechanism of activation. Oncogens 1988;2:399-402.
12. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 1989;41:153-174.
13. Uhlmann E, Peyman A. Antisense oligonuclcotides: a new therapeutic principle. Chem Rev 1990;90:543-584.
14. Postel EH, Flint SJ, Kessler DJ, Hogan ME. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci USA 1991;88:8227-8231.
15. McShan WM, Rossen RD, Laughter AH, et al. Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices. J Biol Chem 1992;267:5712-5721.
16. Okada T, Yamaguchi K, Yamashita Y. Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma. Growth Factors 1994;11:259-270.
17. 125I-labeled oligonucleotides. Nucleic Acids Res 1994;22:4979-4982.